Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy.
In our recent publication (Zheng et al., PLoS ONE) we described the identification of annexin A2 as a new pancreatic cancer associated tumor antigen. Its involvement in pancreatic cancer progression and metastases supports its role as an antigenic target for the development of both therapeutic antibody and T cell immunotherapy.
The Sidney Kimmel Comprehensive Cancer Center; Department of Oncology; The Skip Viragh Center for Pancreatic Cancer; Department of Pathology; The Sol Goldman Pancreatic Cancer Center; Baltimore, MD USA ; Department of Surgery; Johns Hopkins University School of Medicine; Baltimore, MD.
Lei
L
Zheng
Elizabeth M
EM
Jaffee